Testing camonsertib with radiation for returning head and neck cancer
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This study tests whether adding the drug camonsertib to radiation therapy can help people whose head and neck cancer has come back in a spot that was already treated with radiation. Camonsertib is an experimental drug that may help radiation work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that came back in an area that was treated with radiation before.
- It has been at least 6 months since your last radiation therapy to the head and neck.
- You have not had more than one previous round of radiation to the head and neck.
- Your cancer has not spread to distant parts of your body.
- Your tumor does not wrap more than halfway around the main neck artery or invade your jawbone or skin.
- You are able to swallow pills and have adequate organ function (kidneys, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for advanced head and neck cancer in patients who cannot take the drug cisplatin. One group gets radiation plus a targeted drug called cetuximab, the other gets radiation plus standard chemotherapy. The goal is to see which approach works better and is safer for people who are not candidates for cisplatin.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Hear when a new Recurrent Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.